Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001753926-25-001183
Filing Date
2025-07-25
Accepted
2025-07-25 17:26:26
Documents
11
Effectiveness Date
2025-07-25

Document Format Files

Seq Description Document Type Size
1 S-8 g084895_s-8.htm S-8 102325
2 EXHIBIT 4.3 g084895_ex4-3.htm EX-4.3 21320
3 EXHIBIT 5.1 g084895_ex5-1.htm EX-5.1 10960
4 EX-23.1 g084895_ex23-1.htm EX-23.1 1541
5 EXHIBIT 107 g084895_ex107.htm EX-FILING FEES 27522
6 GRAPHIC img001_v1.jpg GRAPHIC 25972
7 GRAPHIC img011.jpg GRAPHIC 18440
8 GRAPHIC img012.jpg GRAPHIC 21004
9 GRAPHIC img013.jpg GRAPHIC 6100
10 GRAPHIC img014.jpg GRAPHIC 8539
11 GRAPHIC image_001.jpg GRAPHIC 362433
  Complete submission text file 0001753926-25-001183.txt   775138
Mailing Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703
Business Address 4020 STIRRUP CREEK DRIVE SUITE 110 DURHAM NC 27703 919-908-2422
Pelthos Therapeutics Inc. (Filer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-288980 | Film No.: 251152479
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)